Lori M Minasian

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Prevention and early detection clinical trials: opportunities for primary care providers and their patients
    Leslie G Ford
    Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA
    CA Cancer J Clin 53:82-101. 2003
  2. pmc Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program
    Lori M Minasian
    Division of Cancer Prevention, U S National Cancer Institute, Rockville, Md Electronic address
    Semin Oncol 42:748-63. 2015
  3. ncbi request reprint Health-related quality of life and symptom management research sponsored by the National Cancer Institute
    Lori M Minasian
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7340, USA
    J Clin Oncol 25:5128-32. 2007
  4. pmc Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials
    Bryce B Reeve
    Affiliations of authors Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC BBR, EB Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD SAM Division of Cancer Prevention, National Cancer Institute, Bethesda, MD LMM and AMO Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD AMD Division of Health Sciences Research, Mayo Clinic, Scottsdale, AZ ACD Feinberg School of Medicine, Northwestern University, Chicago, IL DC Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA CMR, DWB Department of General Oncology, MD Anderson Cancer Center, Houston, TX MJF Mayo Clinic Breast SPORE, Rochester, MN CCh Department of Psychological Research, The Netherlands Cancer Institute, Amsterdam, The Netherlands NKA Quality of Life Department, European Organization for the Research and Treatment of Cancer, Brussels, Belgium CCo
    J Natl Cancer Inst 106:. 2014
  5. ncbi request reprint Research-design issues in cancer-symptom-management trials using complementary and alternative medicine: lessons from the National Cancer Institute Community Clinical Oncology Program experience
    David R Buchanan
    National Cancer Institute, 6130 Executive Plaza, Rm 2149, Bethesda, MD 20892 7317, USA
    J Clin Oncol 23:6682-9. 2005
  6. pmc Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials
    Dawn L Hershman
    Dawn L Hershman, Jason D Wright, and Danielle Awad, Columbia University Medical Center, New York, NY Cathee Till, Scott D Ramsey, and Joseph Unger, Fred Hutchinson Cancer Research Center William E Barlow, University of Washington, Seattle, WA and Lori M Minasian, National Cancer Institute, Bethesda, MD
    J Clin Oncol 34:3014-22. 2016
  7. doi request reprint A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    Barbara K Dunn
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Nutr Cancer 62:896-918. 2010
  8. pmc Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation
    Andrew N Freedman
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7393, USA
    J Natl Cancer Inst 102:1698-705. 2010
  9. pmc Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial
    Joseph M Unger
    SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA JMU, CT, CMT, PJG, WEB Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX IMTJr Columbia University, New York, NY JDW, DLH Fred Hutchinson Cancer Research Center, Seattle, WA SDR Division of Cancer Prevention, U S National Cancer Institute, Rockville, MD LMM
    J Natl Cancer Inst 108:. 2016
  10. pmc Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology Program
    Lori M Minasian
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA
    Cancer 116:4440-9. 2010

Detail Information

Publications18

  1. ncbi request reprint Prevention and early detection clinical trials: opportunities for primary care providers and their patients
    Leslie G Ford
    Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA
    CA Cancer J Clin 53:82-101. 2003
    ....
  2. pmc Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program
    Lori M Minasian
    Division of Cancer Prevention, U S National Cancer Institute, Rockville, Md Electronic address
    Semin Oncol 42:748-63. 2015
    ..These large cancer prevention studies, which have enrolled more than 80,000 volunteers, continue to contribute to our understanding of cancer development more than 10 years after they were closed. ..
  3. ncbi request reprint Health-related quality of life and symptom management research sponsored by the National Cancer Institute
    Lori M Minasian
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7340, USA
    J Clin Oncol 25:5128-32. 2007
    ..The scope of NCI's research in symptom management and HRQOL is described with attention to its evolution over time and the next steps, through the Clinical Trials Working Group Recommendations...
  4. pmc Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials
    Bryce B Reeve
    Affiliations of authors Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC BBR, EB Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD SAM Division of Cancer Prevention, National Cancer Institute, Bethesda, MD LMM and AMO Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD AMD Division of Health Sciences Research, Mayo Clinic, Scottsdale, AZ ACD Feinberg School of Medicine, Northwestern University, Chicago, IL DC Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA CMR, DWB Department of General Oncology, MD Anderson Cancer Center, Houston, TX MJF Mayo Clinic Breast SPORE, Rochester, MN CCh Department of Psychological Research, The Netherlands Cancer Institute, Amsterdam, The Netherlands NKA Quality of Life Department, European Organization for the Research and Treatment of Cancer, Brussels, Belgium CCo
    J Natl Cancer Inst 106:. 2014
    ..We report the results of an evidence-synthesis and consensus-building effort that culminated in recommendations for core symptoms to be measured in adult cancer clinical trials that include a patient-reported outcome (PRO)...
  5. ncbi request reprint Research-design issues in cancer-symptom-management trials using complementary and alternative medicine: lessons from the National Cancer Institute Community Clinical Oncology Program experience
    David R Buchanan
    National Cancer Institute, 6130 Executive Plaza, Rm 2149, Bethesda, MD 20892 7317, USA
    J Clin Oncol 23:6682-9. 2005
    ..To identify major research-design issues in proposals submitted by investigators in the Community Clinical Oncology Program (CCOP) for clinical trials of complementary and alternative medicine (CAM) for cancer-symptom management...
  6. pmc Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials
    Dawn L Hershman
    Dawn L Hershman, Jason D Wright, and Danielle Awad, Columbia University Medical Center, New York, NY Cathee Till, Scott D Ramsey, and Joseph Unger, Fred Hutchinson Cancer Research Center William E Barlow, University of Washington, Seattle, WA and Lori M Minasian, National Cancer Institute, Bethesda, MD
    J Clin Oncol 34:3014-22. 2016
    ..We evaluated the association between common comorbid conditions and the development of peripheral neuropathy in patients treated with taxane-based chemotherapy...
  7. doi request reprint A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    Barbara K Dunn
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Nutr Cancer 62:896-918. 2010
    ..07, P = 0.16) were observed. SELECT data show that neither selenium nor vitamin E, alone or together, in the doses and formulations used, prevented prostate cancer in this heterogeneous population of healthy men...
  8. pmc Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation
    Andrew N Freedman
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7393, USA
    J Natl Cancer Inst 102:1698-705. 2010
    ....
  9. pmc Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial
    Joseph M Unger
    SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA JMU, CT, CMT, PJG, WEB Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX IMTJr Columbia University, New York, NY JDW, DLH Fred Hutchinson Cancer Research Center, Seattle, WA SDR Division of Cancer Prevention, U S National Cancer Institute, Rockville, MD LMM
    J Natl Cancer Inst 108:. 2016
    ..Finasteride has been found to reduce the risk of low-grade prostate cancer but to have no impact on overall survival. The long-term adverse and beneficial consequences of finasteride have not been examined...
  10. pmc Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology Program
    Lori M Minasian
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA
    Cancer 116:4440-9. 2010
    ..By describing its keys to success, this article provides practical guidance to cancer-focused, provider-based research networks as well as those in other disciplines...
  11. ncbi request reprint Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    Eric A Klein
    Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH University of Texas Health Science Center at San Antonio, San Antonio, TX Fred Hutchinson Cancer Research Center, Seattle, WA University of Colorado School of Medicine, Aurora, CO SWOG Statistical Center, Seattle, WA National Cancer Institute, Bethesda, MD Division of Cancer Prevention, National Cancer Institute, Bethesda, MD VA Boston Healthcare System, Massachusetts Veterans Epidemiology Research and Information Center, Boston, MA University of Texas M D Anderson Cancer Center, Houston, TX Mayo Clinic, Rochester, MN Duke University Medical Center, Durham, NC University of California, San Diego Moores Cancer Center, La Jolla, CA London Health Sciences Centre, London, ON, Canada Swedish Cancer Institute, Seattle, WA Chao Family Comprehensive Cancer Center, Orange, CA University of Michigan, Ann Arbor, MI
    J Clin Oncol 30:7. 2012
    ..Longer follow-up and more prostate cancer events provide further insight into the relationship of vitamin E and prostate cancer...
  12. ncbi request reprint Increasing minority participation in cancer clinical trials: the minority-based community clinical oncology program experience
    Worta McCaskill-Stevens
    Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 23:5247-54. 2005
    ..This article examines temporal trends in MBCCOP accruals to cancer prevention and control (CP/C) and cancer treatment trials and the racial distribution of study participants, along with the major factors affecting minority enrollment...
  13. ncbi request reprint Quality-of-life assessment in the symptom management trials of the National Cancer Institute-supported Community Clinical Oncology Program
    David R Buchanan
    Division of Cancer Prevention, National Cancer Institute NIH, 6130 Executive Blvd, Room EPN 2149, Bethesda, MD 20892 7317, USA
    J Clin Oncol 23:591-8. 2005
    ..To examine how quality of life (QOL) is prospectively conceptualized, defined, and measured in the symptom management clinical trials supported by the National Cancer Institute Community Clinical Oncology Program (CCOP)...
  14. pmc Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
    Ethan Basch
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC EB, BBR, AVB Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC EB, BBR, AVB Department of Epidemiology and Biostatistics, Health Outcomes Research Group EB, LS, LR and Department of Psychiatry and Behavioral Sciences JH, TMA, Memorial Sloan Kettering Cancer Center, New York, NY Outcomes Research Branch, Applied Research Program, Division of Cancer Control and Population Sciences SAM, SBC, Division of Cancer Prevention LMM, NCTN Clinical Trials Operations, Cancer Therapy Evaluation Program AD, Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention AMO, DSG, JK, and Investigational Drug Branch, Cancer Therapy Evaluation Program AC, National Cancer Institute, Bethesda, MD Division of Health Sciences Research, College of Medicine, Mayo Clinic Arizona, Scottsdale, Unidad de Salud Respiratoria
    J Natl Cancer Inst 106:. 2014
    ..It is envisioned that the PRO-CTCAE will enhance the precision and patient-centeredness of adverse event reporting in cancer clinical research. ..
  15. pmc Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk
    Alan R Kristal
    Affiliations of authors Cancer Prevention Program ARK and SWOG Statistical Center AKD, CMT, PJG, Fred Hutchinson Cancer Research Center, Seattle, WA Department of Epidemiology ARK, GEG and Department of Environmental Health GEG, University of Washington, Seattle, WA University of Missouri, Research Reactor Center, Columbia, MO JSM Harry S Truman Memorial Veterans Hospital, Columbia, MO JSM Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX IMT Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA FLM Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD LMM, HLP Moores Cancer Center, University of California San Diego, San Diego, CA SML Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH EAK
    J Natl Cancer Inst 106:djt456. 2014
    ..This case-cohort study investigates effects of selenium and vitamin E supplementation conditional upon baseline selenium status...
  16. ncbi request reprint Patient-reported outcomes assessment in cancer trials: taking stock, moving forward
    Joseph Lipscomb
    Emory University, Atlanta, GA 30322, USA
    J Clin Oncol 25:5133-40. 2007
    ....
  17. ncbi request reprint Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    Scott M Lippman
    The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Natl Cancer Inst 97:94-102. 2005
    ....
  18. ncbi request reprint Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    Elise D Cook
    Department of Clinical Cancer Prevention, Unit 1360, The University of Texas M D Anderson Cancer Center, Houston 77230 1439, USA
    Clin Trials 2:436-42. 2005
    ..The goal for black participants was set at 20% because of their proportion in the United States population and their prevalence of prostate cancer...